SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON DC 20549

                                    FORM 8-K

                                 CURRENT REPORT

        Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): August 9, 1999

                           COPLEY PHARMACEUTICAL, INC.
             (Exact name of registrant as specified in its charter)

                                    Delaware
         (State or other jurisdiction of incorporation or organization)

         0-20126                                    04-2514637
(Commission File Number)                   (IRS Employer Identification No.)

25 John Road
Canton, Massachusetts                               02021
(Address of principal executive offices)          (Zip Code)

                               (781) 821-6111
              (Registrant's telephone number, including area code)
<PAGE>
Item 5.           Other Events.

On August 10, 1999 Copley  Pharmaceutical,  Inc.  announced that Copley and Teva
Pharmaceuticals   USA,  Inc.,  Teva   Pharmaceutical   Industries   Ltd.'s  U.S.
subsidiary,  have  executed a  definitive  merger  agreement  providing  for the
acquisition by Teva-USA of all the  outstanding  shares of Copley for $11.00 per
share in cash. The transaction is valued at approximately $220 million.

The  merger  agreement  provides  for a cash  tender  offer  by  Caribou  Merger
Corporation,  a subsidiary  of Teva-USA,  for all  outstanding  Copley shares at
$11.00 per share.  The tender offer will be commenced within five business days.
The tender  offer will be  conditioned  upon,  among other  things,  there being
validly  tendered  and not  withdrawn,  at least a majority  of the  outstanding
shares of Copley,  and the expiration of appropriate  waiting  periods under the
Hart-Scott-Rodino  Antitrust  Act.  The offer is not  subject  to any  financing
condition,  and the obligations of Teva-USA under the merger agreement have been
guaranteed  by Teva  Pharmaceutical  Industries  Limited.  Any Copley shares not
purchased  pursuant to the tender offer will be acquired in a subsequent  merger
at the same $11.00 per share cash price.


Item 7.  Exhibits

99.1 Joint press release of the  Registrant and Teva  Pharmaceutical  Industries
Ltd.
<PAGE>
                              SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


DATE                          COPLEY PHARMACEUTICAL, INC.
August 10, 1999



                              /s/ Daniel M.P. Caron
                              ---------------------
                              Daniel M. P. Caron
                              Vice President, Finance, Chief Financial
                              Officer and Treasurer(Principal Financial Officer)
[{"type": "8-K", "sequence": "1", "description": "MERGER WITH TEVA", "secsgml_size_bytes": 2992}]
{"company-data": {"conformed-name": "COPLEY PHARMACEUTICAL INC", "cik": "0000829987", "assigned-sic": "2834", "irs-number": "042514637", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-20126", "film-number": "99683035"}, "business-address": {"street1": "25 JOHN RD ST 13TH FL", "city": "CANTON", "state": "MA", "zip": "02021", "phone": "7818216111"}, "mail-address": {"street1": "25 JOHN ROAD", "city": "CANTON", "state": "MA", "zip": "02021"}}
SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON DC 20549

                                    FORM 8-K

                                 CURRENT REPORT

        Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): August 9, 1999

                           COPLEY PHARMACEUTICAL, INC.
             (Exact name of registrant as specified in its charter)

                                    Delaware
         (State or other jurisdiction of incorporation or organization)

         0-20126                                    04-2514637
(Commission File Number)                   (IRS Employer Identification No.)

25 John Road
Canton, Massachusetts                               02021
(Address of principal executive offices)          (Zip Code)

                               (781) 821-6111
              (Registrant's telephone number, including area code)
Item 5.           Other Events.

On August 10, 1999 Copley  Pharmaceutical,  Inc.  announced that Copley and Teva
Pharmaceuticals   USA,  Inc.,  Teva   Pharmaceutical   Industries   Ltd.'s  U.S.
subsidiary,  have  executed a  definitive  merger  agreement  providing  for the
acquisition by Teva-USA of all the  outstanding  shares of Copley for $11.00 per
share in cash. The transaction is valued at approximately $220 million.

The  merger  agreement  provides  for a cash  tender  offer  by  Caribou  Merger
Corporation,  a subsidiary  of Teva-USA,  for all  outstanding  Copley shares at
$11.00 per share.  The tender offer will be commenced within five business days.
The tender  offer will be  conditioned  upon,  among other  things,  there being
validly  tendered  and not  withdrawn,  at least a majority  of the  outstanding
shares of Copley,  and the expiration of appropriate  waiting  periods under the
Hart-Scott-Rodino  Antitrust  Act.  The offer is not  subject  to any  financing
condition,  and the obligations of Teva-USA under the merger agreement have been
guaranteed  by Teva  Pharmaceutical  Industries  Limited.  Any Copley shares not
purchased  pursuant to the tender offer will be acquired in a subsequent  merger
at the same $11.00 per share cash price.

Item 7.  Exhibits

99.1 Joint press release of the  Registrant and Teva  Pharmaceutical  Industries
Ltd.
SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

DATE                          COPLEY PHARMACEUTICAL, INC.
August 10, 1999

                              /s/ Daniel M.P. Caron
                              ---------------------
                              Daniel M. P. Caron
                              Vice President, Finance, Chief Financial
                              Officer and Treasurer(Principal Financial Officer)